Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT00539591
PHASE2

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Sponsor: St. Jude Children's Research Hospital

View on ClinicalTrials.gov

Summary

The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.

Key Details

Gender

All

Age Range

Any - 21 Years

Study Type

INTERVENTIONAL

Enrollment

29

Start Date

2008-05-09

Completion Date

2026-05

Last Updated

2025-12-23

Healthy Volunteers

No

Interventions

DRUG

Peginterferon alfa-2b

Given either IV or SQ. Therapeutic drug class: interferon.

DRUG

Temozolomide

Given PO. Therapeutic drug class: antineoplastic agent.

DRUG

Recombinant interferon alfa-2b

Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon

Locations (3)

Rady Children's Hospital

San Diego, California, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

The Children's Cancer Hospital at UT M.D. Anderson Cancer Center

Houston, Texas, United States